RB1 and breast cancer: In a series of breast cancers treated with an adjuvant chemotherapeutic protocol including cyclophosphamide, methotrexate, and 5-fluorouracil, the presence of a wild-type or mutated p53, considered independently of the RB status, proved to have a null prognostic value.